Jazz Pharmaceuticals leukemia new drug Vyxeos gets NICE approval

recently, the National Institutes of Health and Clinical Optimization (NICE) approved the use of the British National Service (NHS) by thePharmaceutical(The Company's(LeukemiaNew Drug(44mg/100mg Infusion Concentrated Powder)its main approval is to treat 2 newly treated adult acute myeloid leukemia (AML) :(1) to treat acute myeloid leukemia (t-AML) ;(2) with changes associated with bone marrow growth abnormality (AML-MRC)VyxeosVyxeos is an advanced lipid system that combines chemotherapydrugs(cytarabine and daunorubicin) with a 5:1 molar ratio and encapsulated in a nanoscale liposome delivery vectorThis nano-lipido delivery vector enhances efficacy while limiting the risk of taking each drug alonein the European Union, Vyxeos was approved at the end of August this year, the first chemotherapy drug in the new t-AML or AML-MRC Phase III study to have a significant overall survival advantage over the current standard 7-3 chemotherapy, and the first chemotherapy drug in Europe dedicated to t-AML and AML-MRCVyxeos' launch will benefit AML adult patients in EuropePreviously, Vyxeos had been granted orphan drug eligibility and accelerated approvaltheof Vyxeos is based on data from five clinical studies, including a critical Phase III clinical study The study was conducted in 309 elderly patients (60-75 years) of high-risk AML who were not previously treated Vyxeos were compared with the standard alyssedoclycinandetic and erythromycin (7-3) chemotherapy regimen data show edified a statistically significant improvement in total survival (OS) in the Vyxeos treatment group compared to the control group (7-3) (median OS: 9.6 months vs 5.9 months, bilateral p.005, HR.95% CI) The rate of total remission increased significantly (37% vs 26%, p.036), and hematopoietic stem cell transplantation (HSCT) (34% vs 25%) in the United States, Vyxeos received FDA (approval) in August 2017 for the aforementioned indications This is the first marketed treatment for a specific type of acute myeloid leukemia (AML), which significantly improves chemotherapy effectiveness and prolongs patient survival by combining 2 commonly used chemotherapy drugs 　　Vyxeos comes with a black-box warning that vyxeos are strictly prohibited from replacing other drugs containing erythromycin or aglycine Previously, Vyxeos has been granted orphan drug qualification, breakthrough drug qualification, priority review qualification by the FDA